25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Zenas BioPharma, Inc. Common Stock
Buy, Hold or Sell?

Let's analyze Zenas BioPharma, Inc. Common Stock together

I guess you are interested in Zenas BioPharma, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zenas BioPharma, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Zenas BioPharma, Inc. Common Stock

I send you an email if I find something interesting about Zenas BioPharma, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Zenas BioPharma, Inc. Common Stock (30 sec.)










1.2. What can you expect buying and holding a share of Zenas BioPharma, Inc. Common Stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-7.26
Expected worth in 1 year
$-14.51
How sure are you?
0.0%

+ What do you gain per year?

Total Gains per Share
$-7.26
Return On Investment
inf%

For what price can you sell your share?

Current Price per Share
$
Expected price per share
$7.0477347972973 - $20.50
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Zenas BioPharma, Inc. Common Stock (5 min.)




Live pricePrice per Share (EOD)
$

2.2. Growth of Zenas BioPharma, Inc. Common Stock (5 min.)




Is Zenas BioPharma, Inc. Common Stock growing?

Current yearPrevious yearGrowGrow %
How rich?-$288.7m???

How much money is Zenas BioPharma, Inc. Common Stock making?

Current yearPrevious yearGrowGrow %
Making money-$13.6m???
Net Profit Margin17.8%?--

How much money comes from the company's main activities?

2.3. Financial Health of Zenas BioPharma, Inc. Common Stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Zenas BioPharma, Inc. Common Stock?

Welcome investor! Zenas BioPharma, Inc. Common Stock's management wants to use your money to grow the business. In return you get a share of Zenas BioPharma, Inc. Common Stock.

First you should know what it really means to hold a share of Zenas BioPharma, Inc. Common Stock. And how you can make/lose money.

Speculation

The Price per Share of Zenas BioPharma, Inc. Common Stock is $. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zenas BioPharma, Inc. Common Stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zenas BioPharma, Inc. Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-7.26. Based on the TTM, the Book Value Change Per Share is $-1.81 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zenas BioPharma, Inc. Common Stock.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.95-0.34-0.34-0.34
Usd Book Value Change Per Share-0.91-1.81-1.81-1.81
Usd Dividend Per Share0.000.000.000.00
Usd Total Gains Per Share-0.91-1.81-1.81-1.81
Usd Price Per Share0.00-0.00-0.00-0.00-
Price to Earnings Ratio0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio
Price to Book Ratio0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio

When do you get the money?

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.03.00.025.0%1.03.00.025.0%1.03.00.025.0%1.03.00.025.0%
Book Value Change Per Share0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%
Dividend per Share0.00.04.00.0%0.00.04.00.0%0.00.04.00.0%0.00.04.00.0%0.00.04.00.0%
Total Gains per Share0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Zenas BioPharma, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.912-1.814+99%---1.814+99%-1.814+99%
Book Value Per Share---7.257-6.089-16%---6.089-16%-6.089-16%
Current Ratio--4.8233.408+42%--3.408+42%3.408+42%
Debt To Asset Ratio--2.4444.079-40%--4.079-40%4.079-40%
Debt To Equity Ratio----0%---0%-0%
Dividend Per Share----0%---0%-0%
Eps---0.954-0.344-64%---0.344-64%-0.344-64%
Free Cash Flow Per Share---0.779-0.212-73%---0.212-73%-0.212-73%
Free Cash Flow To Equity Per Share--3.6881.027+259%--1.027+259%1.027+259%
Gross Profit Margin--1.0001.0000%--1.0000%1.0000%
Market Cap-0%--0%---0%-0%
Net Profit Margin---0.178-100%--0.178-100%0.178-100%
Operating Margin----0%---0%-0%
Operating Ratio---0.072-100%--0.072-100%0.072-100%
Pb Ratio-0%--0%---0%-0%
Pe Ratio-0%--0%---0%-0%
Price Per Share-0%--0%---0%-0%
Price To Free Cash Flow Ratio-0%--0%---0%-0%
Quick Ratio----0%---0%-0%
Return On Assets---0.190-0.173-9%---0.173-9%-0.173-9%
Return On Equity----0%---0%-0%
Total Gains Per Share---0.912-1.814+99%---1.814+99%-1.814+99%
Usd Book Value---288782000.000-242307500.000-16%---242307500.000-16%-242307500.000-16%
Usd Book Value Change Per Share---0.912-1.814+99%---1.814+99%-1.814+99%
Usd Book Value Per Share---7.257-6.089-16%---6.089-16%-6.089-16%
Usd Dividend Per Share----0%---0%-0%
Usd Eps---0.954-0.344-64%---0.344-64%-0.344-64%
Usd Free Cash Flow---30994000.000-8422250.000-73%---8422250.000-73%-8422250.000-73%
Usd Free Cash Flow Per Share---0.779-0.212-73%---0.212-73%-0.212-73%
Usd Free Cash Flow To Equity Per Share--3.6881.027+259%--1.027+259%1.027+259%
Usd Market Cap-0%--0%---0%-0%
Usd Price Per Share-0%--0%---0%-0%
Usd Profit---37977000.000-13689250.000-64%---13689250.000-64%-13689250.000-64%
Usd Revenue---12500000.000-100%--12500000.000-100%12500000.000-100%
Usd Total Gains Per Share---0.912-1.814+99%---1.814+99%-1.814+99%
 EOD+0 -0MRQTTM+9 -12YOY+0 -05Y+9 -1210Y+9 -12

3.3 Fundamental Score

Let's check the fundamental score of Zenas BioPharma, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than14.823
Debt to Asset Ratio (MRQ)Less than12.444
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.190
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Zenas BioPharma, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
Total0/0 (0.0%)

4. In-depth Analysis

4.1 About Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-15 09:41:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Zenas BioPharma, Inc. Common Stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM17.8%-17.8%
TTM17.8%5Y17.8%0.0%
5Y17.8%10Y17.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--120.2%+120.2%
TTM17.8%-210.7%+228.5%
5Y17.8%-348.0%+365.8%
10Y17.8%-473.2%+491.0%
4.3.1.2. Return on Assets

Shows how efficient Zenas BioPharma, Inc. Common Stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • -19.0% Return on Assets means that Zenas BioPharma, Inc. Common Stock generated $-0.19 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is -19.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.0%TTM-17.3%-1.7%
TTM-17.3%5Y-17.3%0.0%
5Y-17.3%10Y-17.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.0%-11.0%-8.0%
TTM-17.3%-11.8%-5.5%
5Y-17.3%-12.6%-4.7%
10Y-17.3%-14.3%-3.0%
4.3.1.3. Return on Equity

Shows how efficient Zenas BioPharma, Inc. Common Stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • 0.0% Return on Equity means Zenas BioPharma, Inc. Common Stock generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.1%+14.1%
TTM--15.8%+15.8%
5Y--18.5%+18.5%
10Y--19.2%+19.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Zenas BioPharma, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Zenas BioPharma, Inc. Common Stock is operating .

  • Measures how much profit Zenas BioPharma, Inc. Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--267.8%+267.8%
TTM--313.4%+313.4%
5Y--385.5%+385.5%
10Y--498.7%+498.7%
4.3.2.2. Operating Ratio

Measures how efficient Zenas BioPharma, Inc. Common Stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.072-0.072
TTM0.0725Y0.0720.000
5Y0.07210Y0.0720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.631-2.631
TTM0.0723.412-3.340
5Y0.0724.788-4.716
10Y0.0726.538-6.466
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Zenas BioPharma, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Zenas BioPharma, Inc. Common Stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.82 means the company has $4.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 4.823. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.408. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.823TTM3.408+1.415
TTM3.4085Y3.4080.000
5Y3.40810Y3.4080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8233.690+1.133
TTM3.4083.875-0.467
5Y3.4085.946-2.538
10Y3.4086.274-2.866
4.4.3.2. Quick Ratio

Measures if Zenas BioPharma, Inc. Common Stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.122-3.122
TTM-3.451-3.451
5Y-5.922-5.922
10Y-6.414-6.414
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Zenas BioPharma, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Zenas BioPharma, Inc. Common Stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.44 means that Zenas BioPharma, Inc. Common Stock assets are financed with 244.4% credit (debt) and the remaining percentage (100% - 244.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 2.444. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 4.079. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.444TTM4.079-1.635
TTM4.0795Y4.0790.000
5Y4.07910Y4.0790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4440.353+2.091
TTM4.0790.350+3.729
5Y4.0790.367+3.712
10Y4.0790.382+3.697
4.5.4.2. Debt to Equity Ratio

Measures if Zenas BioPharma, Inc. Common Stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.435-0.435
5Y-0.451-0.451
10Y-0.493-0.493
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zenas BioPharma, Inc. Common Stock generates.

  • Above 15 is considered overpriced but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD-MRQ-0.000
MRQ-TTM-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD--2.126+2.126
MRQ--2.454+2.454
TTM--3.147+3.147
5Y--6.070+6.070
10Y--6.597+6.597
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD-MRQ-0.000
MRQ-TTM-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD--2.981+2.981
MRQ--3.363+3.363
TTM--3.667+3.667
5Y--8.343+8.343
10Y--9.276+9.276
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Zenas BioPharma, Inc. Common Stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.00 means the investor is paying $0.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zenas BioPharma, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD-MRQ-0.000
MRQ-TTM-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.863-1.863
MRQ-2.028-2.028
TTM-2.339-2.339
5Y-3.666-3.666
10Y-4.360-4.360
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets199,952
Total Liabilities488,734
Total Stockholder Equity-288,782
 As reported
Total Liabilities 488,734
Total Stockholder Equity+ -288,782
Total Assets = 199,952

Assets

Total Assets199,952
Total Current Assets188,600
Long-term Assets11,352
Total Current Assets
Cash And Cash Equivalents 183,930
Other Current Assets 4,670
Total Current Assets  (as reported)188,600
Total Current Assets  (calculated)188,600
+/-0
Long-term Assets
Property Plant Equipment 706
Long-term Assets Other 185
Long-term Assets  (as reported)11,352
Long-term Assets  (calculated)891
+/- 10,461

Liabilities & Shareholders' Equity

Total Current Liabilities39,108
Long-term Liabilities449,626
Total Stockholder Equity-288,782
Total Current Liabilities
Accounts payable 8,358
Other Current Liabilities 530
Total Current Liabilities  (as reported)39,108
Total Current Liabilities  (calculated)8,888
+/- 30,220
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt508
Long-term Liabilities  (as reported)449,626
Long-term Liabilities  (calculated)508
+/- 449,118
Total Stockholder Equity
Retained Earnings -296,180
Total Stockholder Equity (as reported)-288,782
Total Stockholder Equity (calculated)-296,180
+/- 7,398
Other
Capital Stock1
Net Invested Capital -288,782
Net Working Capital 149,492
Property Plant and Equipment Gross 706



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302022-12-31
> Total Assets 
74,579
83,792
68,180
49,051
199,952
199,95249,05168,18083,79274,579
   > Total Current Assets 
68,444
76,676
59,804
39,705
188,600
188,60039,70559,80476,67668,444
       Cash And Cash Equivalents 
67,209
72,311
56,857
37,154
183,930
183,93037,15456,85772,31167,209
       Other Current Assets 
1,235
4,365
2,947
2,551
4,670
4,6702,5512,9474,3651,235
   > Long-term Assets 
6,135
7,116
8,376
9,346
11,352
11,3529,3468,3767,1166,135
       Property Plant Equipment 
1,801
1,147
1,014
847
706
7068471,0141,1471,801
       Long-term Assets Other 
212
5,969
186
184
185
1851841865,969212
> Total Liabilities 
266,865
286,024
293,901
301,546
488,734
488,734301,546293,901286,024266,865
   > Total Current Liabilities 
25,967
15,557
23,258
30,333
39,108
39,10830,33323,25815,55725,967
       Accounts payable 
5,815
2,276
5,396
8,830
8,358
8,3588,8305,3962,2765,815
       Other Current Liabilities 
0
0
0
1,500
530
5301,500000
   > Long-term Liabilities 
240,898
270,467
270,643
271,213
449,626
449,626271,213270,643270,467240,898
       Capital Lease Obligations Min Short Term Debt
1,527
964
813
649
508
5086498139641,527
> Total Stockholder Equity
-192,286
-202,232
-225,721
-252,495
-288,782
-288,782-252,495-225,721-202,232-192,286
   Common Stock00000
   Retained Earnings -296,180-258,203-230,403-205,816-193,279
   Capital Surplus 00000
   Treasury Stock00000
   Other Stockholders Equity 00000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue50,000
Cost of Revenue-0
Gross Profit050,000
 
Operating Income (+$)
Gross Profit0
Operating Expense-77,147
Operating Income-27,147-77,147
 
Operating Expense (+$)
Research Development60,033
Selling General Administrative17,114
Selling And Marketing Expenses0
Operating Expense77,14777,147
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-27,147
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-36,823-17,471
EBIT - interestExpense = 0
-37,124
-37,124
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-36,823
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-36,823
Tax Provision-301
Net Income From Continuing Ops-37,124-37,124
Net Income-37,124
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-9,6760
 

1.4. Technical Score

Let's check the technical score of Zenas BioPharma, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
Total0/0 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Zenas BioPharma, Inc. Common Stock with someone you think should read this too:
  • Are you bullish or bearish on Zenas BioPharma, Inc. Common Stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zenas BioPharma, Inc. Common Stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zenas BioPharma, Inc. Common Stock

I send you an email if I find something interesting about Zenas BioPharma, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Zenas BioPharma, Inc. Common Stock.

Receive notifications about Zenas BioPharma, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.